UB Paderborn / Katalog / Suche / in CDI

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

1 – 25 von 1.287

Sortiert nach

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Journal of clinical oncology, 2015-08, Vol.33 (23), p.2492-2499

2015

Volltextzugriff (PDF)

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Clinical cancer research, 2017-07, Vol.23 (13), p.3307-3315

2017

Volltextzugriff (PDF)

Histone lysine demethylases as targets for anticancer therapy

Nature reviews. Drug discovery, 2013-12, Vol.12 (12), p.917-930

2013

Volltextzugriff (PDF)

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study

Blood, 2021-04, Vol.137 (16), p.2161-2170

2021

Volltextzugriff (PDF)

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

The lancet oncology, 2018-09, Vol.19 (9), p.1192-1204

2018

Volltextzugriff (PDF)

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

Biochemical pharmacology, 2020-12, Vol.182, p.114224-114224, Article 114224

2020

Volltextzugriff (PDF)

Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma

Clinical cancer research, 2017-09, Vol.23 (17), p.5187-5201

2017

Volltextzugriff (PDF)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

British journal of cancer, 2011-06, Vol.104 (12), p.1828-1835

2011

Volltextzugriff (PDF)

Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition

Antioxidants & redox signaling, 2015-06, Vol.22 (16), p.1382

2015

Volltextzugriff (PDF)

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

British journal of haematology, 2015-03, Vol.168 (6), p.811-819

2015

Volltextzugriff (PDF)

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

Nature (London), 2012-07, Vol.487 (7408), p.482-485

2012

Volltextzugriff (PDF)

The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation

International journal of molecular sciences, 2018-06, Vol.19 (6), p.1754

2018

Volltextzugriff (PDF)

Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies

Journal of clinical oncology, 2017-04, Vol.35 (11), p.1231-1239

2017

Volltextzugriff (PDF)

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

The Journal of clinical investigation, 2017-08, Vol.127 (8), p.3126-3135

2017

Volltextzugriff (PDF)

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Journal of clinical oncology, 2021-10, Vol.39 (28), p.3171-3181

2021

Volltextzugriff (PDF)

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

Proceedings of the National Academy of Sciences - PNAS, 2014-08, Vol.111 (32), p.11774-11779

2014

Volltextzugriff (PDF)

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

The Lancet (British edition), 2020-03, Vol.395 (10227), p.888-898

2020

Volltextzugriff (PDF)

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

The lancet oncology, 2016-05, Vol.17 (5), p.622-631

2016

Volltextzugriff (PDF)

Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Cancer, 2020-05, Vol.126 (9), p.2024-2033

2020

Volltextzugriff (PDF)

The future of epigenetic therapy in solid tumours--lessons from the past

Nature reviews. Clinical oncology, 2013-05, Vol.10 (5), p.256-266

2013

Volltextzugriff (PDF)

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

Haematologica (Roma), 2017-11, Vol.102 (11), p.1923

2017

Volltextzugriff (PDF)

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma

British journal of haematology, 2017-08, Vol.178 (3), p.434-441

2017

Volltextzugriff (PDF)

c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer

Clinical cancer research, 2017-05, Vol.23 (10), p.2542-2555

2017

Volltextzugriff (PDF)

Combination Therapies Targeting HDAC and IKK in Solid Tumors

Trends in pharmacological sciences (Regular ed.), 2018-03, Vol.39 (3), p.295-306

2018

Volltextzugriff (PDF)

HDAC1 regulates fear extinction in mice

The Journal of neuroscience, 2012-04, Vol.32 (15), p.5062-5073

2012

Volltextzugriff (PDF)

1 – 25 von 1.287

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.205)
Mit Volltextzugriff
(1.190)

Publikationsform

Artikel
(1.286)
Tagungsberichte
(1)

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

n.n

Thema

Science & Technology
(1.202)
Life Sciences & Biomedicine
(1.134)
Humans
(1.028)
Histone Deacetylase Inhibitors - Administration & Dosage
(635)
Animals
(611)
Oncology
(566)
Male
(454)
Female
(425)
Hydroxamic Acids - Administration & Dosage
(398)
Mice
(387)
Cell Line, Tumor
(369)
Histone Deacetylase Inhibitors - Pharmacology
(361)
Histone Deacetylase
(332)
Histone Deacetylase Inhibitors
(310)
Biological And Medical Sciences
(252)
Apoptosis
(240)
Apoptosis - Drug Effects
(234)
Tumors
(232)
Medical Sciences
(230)
Pharmacology & Pharmacy
(214)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(1.258)
Free E-Journal (出版社公開部分のみ）
(721)
Ingenta
(608)
Journals@Ovid Full Text
(462)
IngentaConnect Journals
(380)
Publisher website
(259)
Access via ScienceDirect (Elsevier)
(218)
springer (창간호~2014)
(197)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(176)
Wiley Blackwell Single Titles
(131)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(116)
Nature Journals
(111)
Wiley Online Library
(96)
Nexis
(86)
Access via Taylor & Francis
(86)
Taylor & Francis
(83)
Taylor & Francis Journals Complete
(59)
Oxford journals
(29)
Oxford Journals 2020 Medicine
(24)
SAGE Journals
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Cancer Research
(60)
Plos One
(39)
Cancer Research
(24)
Investigational New Drugs
(24)
Blood
(23)
Cancer Chemotherapy And Pharmacology
(22)
Oncotarget
(22)
British Journal Of Haematology
(21)
Molecular Cancer Therapeutics
(20)
British Journal Of Cancer
(19)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)